Central serous chorioretinopathy: an update on pathogenesis and treatment.
about
The Choroid and Optical Coherence TomographyHalf-dose verteporfin combined with half-fluence photodynamic therapy for chronic central serous chorioretinopathy.Corticosteroid-associated atypical central serous chorioretinopathy in a patient with multiple sclerosis.Spectral domain optical coherence tomography in patients after successful management of postoperative endophthalmitis following cataract surgery by pars plana vitrectomyReproducibility of choroidal thickness measurements across three spectral domain optical coherence tomography systems.The incidence of central serous chorioretinopathy after photorefractive keratectomy and laser in situ keratomileusis.Intravitreal bevacizumab for iatrogenic choroidal neovascularization due to laser photocoagulation in central serous chorioretinopathy.Central serous chorioretinopathy: update on pathophysiology and treatment.Correlation of subretinal fluid volume with choroidal thickness and macular volume in acute central serous chorioretinopathy.Epidemiology of idiopathic central serous chorioretinopathy in Taiwan, 2001-2006: a population-based study.Exudative detachment as a masquerader in hypoalbuminaemic patientsOral eplerenone for the management of chronic central serous chorioretinopathy.Short-term efficacy of subthreshold micropulse yellow laser (577-nm) photocoagulation for chronic central serous chorioretinopathy.Comparing half-dose photodynamic therapy with high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy (the PLACE trial): study protocol for a randomized controlled trial.Photodynamic therapy and anti-vascular endothelial growth factor for acute central serous chorioretinopathy: a systematic review and meta-analysis.Half-dose photodynamic therapy followed by diode micropulse laser therapy as treatment for chronic central serous chorioretinopathy: evaluation of a prospective treatment protocol.Choroidal imaging using spectral-domain optical coherence tomography.Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathyComparison of subthreshold micropulse laser (577 nm) treatment and half-dose photodynamic therapy in patients with chronic central serous chorioretinopathyReproducibility of choroidal thickness measurements in subjects on 3 spectral domain optical coherence tomography machines.Clinical efficacy of anti-VEGF medications for central serous chorioretinopathy: a meta-analysis.Atypical chronic central serous chorioretinopathy with cystoid macular edema: Therapeutic response to medical and laser therapy.Change in subfoveal choroidal thickness in central serous chorioretinopathy following spontaneous resolution and low-fluence photodynamic therapy.Efficacy of half-fluence photodynamic therapy depending on the degree of choroidal hyperpermeability in chronic central serous chorioretinopathy.Half-dose Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.Angiographic characteristics of central serous chorioretinopathy in an Egyptian population.Analysis of choroidal morphologic features and vasculature in healthy eyes using spectral-domain optical coherence tomographyCentral serous chorioretinopathy in primary hyperaldosteronismOcular cysticercosis in a 32-year-old man in Abuja: ultrasonic features as an aid in diagnosis.Effect of half adult dose of oral Rifampicin (300mg) in patients with idiopathic central serous chorioretinopathyCollaborative care of non-urgent macular disease: a study of inter-optometric referralsSubfoveal Choroidal Thickness in Central Serous Chorioretinopathy: A Meta-Analysis.Aldosterone and vascular mineralocorticoid receptors: regulators of ion channels beyond the kidney.Comparison of autofluorescence and optical coherence tomography findings in acute and chronic central serous chorioretinopathy.Evaluation of verteporfin pharmakokinetics--redefining the need of photosensitizers in ophthalmology.Central serous chorioretinopathy: a review of epidemiology and pathophysiology.Optical coherence tomography--current and future applicationsLack of positive effect of intravitreal bevacizumab in central serous chorioretinopathy: meta-analysis and review.Unintentional secondary exogenous corticosteroid exposure and central serous chorioretinopathyFundus autofluorescence applications in retinal imaging.
P2860
Q28076108-9BF2864D-C07B-4349-BB79-3C9A88DA6A82Q33705962-FDF1487E-56E7-4FB9-BE2E-DA9F82099427Q33706152-51220D4A-0818-424A-8D25-BEC0F2B87C54Q33830594-2280CC8A-5A6E-404A-A301-77CE4C0D7860Q34029765-667EFC8D-806E-4EFB-8F49-68C4AE33D6D4Q34240123-3D001D8C-952B-4E12-B2BA-57E58BE1309BQ34242671-085C1393-FDA9-4AD3-B0A8-B8E6D870EF01Q34587658-A7F7027B-2617-4BDB-ABCC-97B96C73C98EQ34718462-675EA396-17FC-4759-BC38-C86FA15438FFQ34796150-CADCB746-4A0D-4805-988B-195C699B6910Q35227675-23252748-F88A-45D7-BF0C-36D90312249CQ35549958-73AD851F-8772-4D7F-9CD0-431BF38F6037Q35567966-E6FCEF49-FA95-47C5-9EA0-A296156D6088Q35782233-D06A5ABD-EB61-4807-94B8-6A2C6FDBC8AAQ35826493-F724A4FF-9C6F-4E2D-BA98-C81D5251B45FQ35869490-D99512C9-AA10-4F20-A042-A1E439BC7D9EQ36053993-8441C025-D12D-41E1-8F19-58D2A5394EA8Q36068308-DBEA09F8-241C-43F7-A9F8-05A4A71E089FQ36071607-491EA1AA-2296-4F3D-ACC2-63DF8099110AQ36112222-B52B2F06-A974-42C3-B764-A29275402F35Q36339246-CDEFD69D-FD00-4E22-885F-441911EB926CQ36408674-AC9FDC6D-5200-4509-9BBE-569AB48425FEQ36685428-2DF28C0B-2564-4F2B-BC79-7C2948AA4771Q36685488-29201EB1-9F95-4F3E-8615-C968A600C68DQ36883236-15E68838-0262-442E-AF70-E8CD7CACD45AQ36955739-CD940EAE-0A7D-4D55-AEE3-A9591C1EBBF9Q37097755-49CF9695-7194-46E0-8250-A49B7F038FDFQ37302044-0DC47DF1-CA35-44A6-B620-CC85F4E6BEF2Q37378536-C513B54B-86BC-4A04-A62B-7F9B375ED196Q37405446-47D62F4A-61E2-4DB6-90E0-8965FE8B0A1FQ37456542-120E2309-BEF3-465F-B93D-57D59C61BF0DQ37580515-9A4B426C-4113-432B-ACB0-0A1618CEA8BDQ37638481-2D3E4E85-F070-4CFA-A331-1B72A48E0A7DQ37729439-BF356ECC-2B68-4F90-98B0-CFA44F7A6E9AQ38023892-4D860149-0DE1-4C38-90B3-53B5E5A462F7Q38025702-3737A252-25D8-4956-8362-2AEBFD7A7C82Q38083506-B99D413C-80D8-4218-A8B3-FA17B31D90A0Q38160720-27769A70-63C8-4625-B5C7-F722BA574DFEQ38319742-DF3DDFB2-F8F1-41DA-8BF8-273FC5B680F1Q38542359-5C297321-0A6D-41E1-9A0A-6CD2C30592F5
P2860
Central serous chorioretinopathy: an update on pathogenesis and treatment.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Central serous chorioretinopathy: an update on pathogenesis and treatment.
@ast
Central serous chorioretinopathy: an update on pathogenesis and treatment.
@en
type
label
Central serous chorioretinopathy: an update on pathogenesis and treatment.
@ast
Central serous chorioretinopathy: an update on pathogenesis and treatment.
@en
prefLabel
Central serous chorioretinopathy: an update on pathogenesis and treatment.
@ast
Central serous chorioretinopathy: an update on pathogenesis and treatment.
@en
P2093
P356
P1433
P1476
Central serous chorioretinopathy: an update on pathogenesis and treatment.
@en
P2093
A J Lotery
G De Salvo
M Gemenetzi
P2888
P304
P356
10.1038/EYE.2010.130
P577
2010-10-08T00:00:00Z
P5875
P6179
1003930587